Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/SLC16A1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/SLC16A1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/SLC16A1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/SLC16A1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/SLC16A1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/SLC16A1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/SLC16A1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00716921 | Colorectum | SER | protein localization to extracellular region | 80/2897 | 368/18723 | 8.13e-04 | 1.01e-02 | 80 |
GO:00300731 | Colorectum | SER | insulin secretion | 46/2897 | 195/18723 | 1.86e-03 | 1.90e-02 | 46 |
GO:00507961 | Colorectum | SER | regulation of insulin secretion | 40/2897 | 165/18723 | 2.10e-03 | 2.06e-02 | 40 |
GO:00425931 | Colorectum | SER | glucose homeostasis | 57/2897 | 258/18723 | 2.92e-03 | 2.59e-02 | 57 |
GO:00158331 | Colorectum | SER | peptide transport | 58/2897 | 264/18723 | 3.08e-03 | 2.70e-02 | 58 |
GO:00335001 | Colorectum | SER | carbohydrate homeostasis | 57/2897 | 259/18723 | 3.20e-03 | 2.76e-02 | 57 |
GO:00900871 | Colorectum | SER | regulation of peptide transport | 46/2897 | 202/18723 | 3.86e-03 | 3.18e-02 | 46 |
GO:00027911 | Colorectum | SER | regulation of peptide secretion | 45/2897 | 200/18723 | 5.35e-03 | 4.03e-02 | 45 |
GO:00902761 | Colorectum | SER | regulation of peptide hormone secretion | 44/2897 | 196/18723 | 6.08e-03 | 4.42e-02 | 44 |
GO:00316672 | Colorectum | MSS | response to nutrient levels | 125/3467 | 474/18723 | 1.24e-05 | 2.88e-04 | 125 |
GO:00335002 | Colorectum | MSS | carbohydrate homeostasis | 76/3467 | 259/18723 | 1.37e-05 | 3.14e-04 | 76 |
GO:00507082 | Colorectum | MSS | regulation of protein secretion | 78/3467 | 268/18723 | 1.47e-05 | 3.33e-04 | 78 |
GO:00425932 | Colorectum | MSS | glucose homeostasis | 75/3467 | 258/18723 | 2.22e-05 | 4.69e-04 | 75 |
GO:00093062 | Colorectum | MSS | protein secretion | 98/3467 | 359/18723 | 2.43e-05 | 5.09e-04 | 98 |
GO:00355922 | Colorectum | MSS | establishment of protein localization to extracellular region | 98/3467 | 360/18723 | 2.75e-05 | 5.58e-04 | 98 |
GO:00716922 | Colorectum | MSS | protein localization to extracellular region | 99/3467 | 368/18723 | 4.17e-05 | 7.83e-04 | 99 |
GO:00507962 | Colorectum | MSS | regulation of insulin secretion | 50/3467 | 165/18723 | 1.61e-04 | 2.31e-03 | 50 |
GO:00300732 | Colorectum | MSS | insulin secretion | 56/3467 | 195/18723 | 3.21e-04 | 4.18e-03 | 56 |
GO:00158332 | Colorectum | MSS | peptide transport | 71/3467 | 264/18723 | 4.79e-04 | 5.60e-03 | 71 |
GO:00900872 | Colorectum | MSS | regulation of peptide transport | 55/3467 | 202/18723 | 1.44e-03 | 1.34e-02 | 55 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC16A1 | SNV | Missense_Mutation | rs151166713 | c.1285G>A | p.Val429Ile | p.V429I | P53985 | protein_coding | tolerated(1) | benign(0.012) | TCGA-A2-A25E-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | PD |
SLC16A1 | SNV | Missense_Mutation | novel | c.1007C>T | p.Ser336Phe | p.S336F | P53985 | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
SLC16A1 | SNV | Missense_Mutation | | c.402G>T | p.Met134Ile | p.M134I | P53985 | protein_coding | tolerated(0.56) | benign(0.013) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
SLC16A1 | SNV | Missense_Mutation | rs759149434 | c.256C>T | p.Arg86Cys | p.R86C | P53985 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLC16A1 | SNV | Missense_Mutation | novel | c.992N>G | p.Tyr331Cys | p.Y331C | P53985 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-D8-A13Z-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD |
SLC16A1 | SNV | Missense_Mutation | | c.867N>C | p.Lys289Asn | p.K289N | P53985 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLC16A1 | SNV | Missense_Mutation | rs746931470 | c.1250N>A | p.Gly417Glu | p.G417E | P53985 | protein_coding | deleterious(0.02) | possibly_damaging(0.597) | TCGA-E2-A15K-06 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
SLC16A1 | SNV | Missense_Mutation | | c.81C>G | p.Phe27Leu | p.F27L | P53985 | protein_coding | deleterious(0.01) | probably_damaging(0.995) | TCGA-E2-A1IH-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | aromasin | SD |
SLC16A1 | insertion | Frame_Shift_Ins | rs606231309 | c.41dupC | p.Asp15ArgfsTer34 | p.D15Rfs*34 | P53985 | protein_coding | | | TCGA-AN-A0FV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SLC16A1 | SNV | Missense_Mutation | novel | c.1499N>G | p.Val500Gly | p.V500G | P53985 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.637) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6566 | SLC16A1 | TRANSPORTER, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | | BUTYRATE | | 11882670 |
6566 | SLC16A1 | TRANSPORTER, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | | SODIUM BUTYRATE | | 11882670 |
6566 | SLC16A1 | TRANSPORTER, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | inhibitor | 404859052 | | |
6566 | SLC16A1 | TRANSPORTER, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | inhibitor | 252827471 | | |
6566 | SLC16A1 | TRANSPORTER, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | | PMA | | 14525727 |
6566 | SLC16A1 | TRANSPORTER, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | inhibitor | 384403683 | | |